A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Trial Profile

A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Sirolimus (Primary) ; Fludarabine; Mycophenolate mofetil
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top